FIELD: biotechnology.
SUBSTANCE: invention relates to fused proteins with anti-tumor activity, and can be used in medicine for anticancer therapy. Fusion polypeptide contains an antibody or a fragment thereof binding to a tumor-specific antigen selected from mesothelin, PD-L1 (programmed death ligand 1), Her2 (EGFR-related human protein 2), CD19, MUC1, EGFR and VEGFR; linker and protein inducing natural killers (NK) from CXCL16. Fused peptide can be obtained by a recombinant method. Also disclosed are pharmaceutical compositions containing said fused peptide, and a method of treating cancer.
EFFECT: invention provides an anti-cancer effect ensured by induction of NK cell migration.
12 cl, 32 dwg, 4 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-NK-CELLS | 2020 |
|
RU2795443C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
| CELL | 2015 |
|
RU2768019C2 |
| NK INVOLVING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2812481C2 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| CRYOPRESERVED CELLS ARE NATURAL KILLERS PRELOADED WITH ANTIBODY CONSTRUCTION | 2019 |
|
RU2819927C2 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| BISPECIFIC ANTIGEN-BINDING PROTEIN EGFR/CD16 | 2019 |
|
RU2792240C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
| ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
